8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): September 8, 2015

ContraFect Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware	001-36577	39-2072586
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

28 Wells Avenue, Third Floor Yonkers, New York	10701
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (914) 207-2300

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) Appointment of Certain Officers

ContraFect Corporation (the “Company”) has appointed Joshua Muntner to serve as Senior Vice President of Business Development of the Company, effective as of August 24, 2015. Mr. Muntner, 46, brings over 15 years of healthcare investment banking experience to ContraFect, and has been involved with a wide range of capital markets and advisory transactions with approximately USD 11bn in value. Most recently, Mr. Muntner was a Managing Director and Co-Head of Healthcare Investment Banking at Janney Montgomery Scott, where he was responsible for originating and executing equity financing and M&A transactions for the firm’s life science clients. Prior to Janney, Mr. Muntner served as Managing Director at ThinkEquity, where he re-established the firm’s healthcare banking practice. Mr. Muntner spent nine years at Oppenheimer & Co. and its predecessor, CIBC World Markets, after starting his investment banking career at Prudential Securities. Mr. Muntner received his MBA from the UCLA Anderson School of Management and a Bachelor of Fine Arts from Carnegie Mellon University.

Item 8.01 Other Events.

On September 8, 2015, the Company issued a press release announcing the appointment of Mr. Muntner. A copy of the press release is filed as Exhibit 99.1 hereto, which is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release of the Company, dated September 8, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	CONTRAFECT CORPORATION
Date: September 8, 2015	By:	/s/ Julia P. Gregory
		Name: Julia P. Gregory
		Title: Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release of the Company, dated September 8, 2015

EX-99.1

Exhibit 99.1

Press Release

ContraFect Appoints Key Business Executives

Josh Muntner Joins as SVP of Business Development and Paul Boni as Head of Investor Development and Strategy

YONKERS, NY — (Marketwired) — 09/08/15 — ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced that it has expanded its senior management team with appointments of Josh Muntner as SVP of Business Development and Paul Boni as Head of Investor Development and Strategy.

“We are pleased to have attracted someone of Josh Muntner’s caliber to lead ContraFect’s business development efforts. The wealth of Josh’s life science transaction experience and deep corporate and investment banking relationships will be tremendously valuable as we plan to expand our company through potential acquisitions and corporate partnerships in the anti-infectives field,” said Julia Gregory, President and Chief Executive Officer of ContraFect. “We’re also delighted to have a seasoned investment professional such as Paul to lead our investor relations efforts. Paul has experience as both an investment manager and a sellside analyst and is well positioned to further expand our institutional shareholder base as we advance our breakthrough lysin and monoclonal antibody platforms.”

Josh Muntner brings over 15 years of healthcare investment banking experience to ContraFect, and has been involved with a wide range of capital markets and advisory transactions with approximately $11bn in value. Most recently, Mr. Muntner was a Managing Director and Co-Head of Healthcare Investment Banking at Janney Montgomery Scott, where he was responsible for originating and executing equity financing and M&A transactions for the firm’s life science clients. Prior to Janney, Mr. Muntner served as Managing Director at ThinkEquity, where he re-established the firm’s healthcare banking practice. Mr. Muntner spent nine years at Oppenheimer & Co. and its predecessor, CIBC World Markets, after starting his investment banking career at Prudential Securities. Mr. Muntner received his MBA from the UCLA Anderson School of Management and a Bachelor of Fine Arts from Carnegie Mellon University.

Paul Boni has over 14 years of experience as an investor, analyst and executive in the biotechnology industry. Prior to joining ContraFect, Mr. Boni was the Global Head of Research at Integreon, where he was in charge of the firm’s strategic research business and carried out special project work for its key life science and financial services clients. Previously, Mr. Boni worked as an analyst/portfolio manager at PAW Partners where he

covered healthcare investments. Before moving to the buy-side, Mr. Boni also served as Vice President of Equity Research at Punk, Ziegel and Company (later acquired by Ladenburg Thalmann Financial Services) and also covered biotechnology stocks at Mehta and Isaly (later split into Orbimed Advisors and Mehta Partners). Mr. Boni received his BS from Harvard College with honors in Biology.

About ContraFect

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital-acquired infections are currently the fourth leading cause of death in the United States, behind heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect’s initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “potential,” “expand,” “advance” or similar references to future periods. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including those detailed in ContraFect’s filings with the Securities and Exchange Commission. Specific forward-looking statements in this release include statements regarding the anticipated value that our new senior team management members will bring, our ability to expand our company and our institutional shareholder base, and our ability to advance our lysin and antibody platforms to address drug-resistant infections, all of which are subject to certain assumptions, risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contacts

Paul Boni

ContraFect Corporation

Tel: 914-207-2317

Email: Email Contact

Barbara Ryan

Clermont Partners

Tel: 203-274-2825

Email: Email Contact

Source: ContraFect Corporation